Frans Kuypers
Frans Kuypers is a biomedical researcher working in hematology, cellular metabolism, and stem cell biology. His research includes investigating the human placenta as a source of pluripotent and hematopoietic stem cells capable of differentiating into various cell types. His published work focuses extensively on sickle cell disease therapeutics, erythrocyte properties and deformability, and lipid metabolism.
12 claims checked on air: 1 context 1 contradicted 9 supported 1 unverified 1 flagged
What they said on air - citing their own research
1 citing their own research
Frans Kuypers published papers in 2009 and 2012 demonstrating that cells isolated from human term placenta can be cultured to differentiate into multiple cell types such as neurons and heart cells.
"And yes, we have shown in 2009, the paper that you refer to, but we had another paper in 2012 that really shows that in the human term placenta—so this is the placenta that is normally thrown out... you can tease out of those placentas cells that can become any kind of cell in your body." (said at 0:09:20)
Frans Kuypers and colleagues published studies in 2009 and 2012 demonstrating that cells isolated from human term placenta can generate multiple cell lineages. The 2009 study isolated CD34-positive hematopoietic stem and progenitor cells from term placenta that generated erythroid, myeloid, and lymphoid lineages. The 2012 study isolated human chorionic mesenchymal stem cells (hCMSCs) expressing embryonic stem cell markers (such as OCT-4 and NANOG) that demonstrated in vitro differentiation into cell types representing all three germ layers, including neuron-like cells (ectoderm), adipocytes/osteoblasts/endothelial-like cells (mesoderm), and hepatocytes (endoderm).
- supports: Human term placenta as a source of hematopoietic cells. (Experimental biology and medicine (Maywood, N.J.) 2009) · cited 48x in the literature
"Here we show that the human placenta contains large numbers of CD34-expressing hematopoietic cells, with the potential to provide a cellular yield several-fold greater than that of a typical UCB harvest. Cells from fresh or cryopreserved placental tissue generated erythroid and myeloid colonies in culture, and also produced lymphoid cells after transplantation in immunodeficient mice." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Multipotent stromal stem cells from human placenta demonstrate high therapeutic potential. (Stem cells translational medicine 2012) · cited 61x in the literature
"In vitro, cells could be differentiated into neuron-like cells (ectoderm), adipocytes, osteoblasts, endothelial-like cells (mesoderm), and hepatocytes (endoderm)-derivatives of all three germ layers." (abstract, results, passage verified)
pubmedfull study (doi)
Fact-checked episodes
Publications
- FT-4202, a selective pyruvate kinase R activator for sickle cell disease.Experimental hematology 2025 · CEBM Level 5
- The RoxyScan is a novel measurement of red blood cell deformability under oxidative and shear stress.Scientific reports 2024 · CEBM Level 5
- Multicenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell disease.Blood advances 2024 · CEBM Level 2
- Assessment of total and unbound cell-free heme in plasma of patients with sickle cell disease.Experimental biology and medicine (Maywood, N.J.) 2023 · CEBM Level 4
- Effect of voxelotor on cardiopulmonary testing in youths with sickle cell anemia in a pilot study.Pediatric blood & cancer 2023 · CEBM Level 4
- Change in Metabolomic Profile Associated with an Average Increase in Plain Water Intake of >+ 1 L/Day, Sustained Over 4 Weeks, in Healthy Young Men with Initial Total Water Intake Below 2 L/Day.Paracelsus proceedings of experimental medicine 2023 · CEBM Level 4
- Differential roles for ACBD4 and ACBD5 in peroxisome-ER interactions and lipid metabolism.The Journal of biological chemistry 2023 · CEBM Level 5
- Implications for the metabolic fate of oral glutamine supplementation within plasma and erythrocytes of patients with sickle cell disease: A pharmacokinetics study.Complementary therapies in medicine 2022 · CEBM Level 4
- The ektacytometric elongation Index (EI) of erythrocytes, validation of a prognostic, rheological biomarker for patients with sickle cell disease.European journal of haematology 2022 · CEBM Level 4
- Correction: Requirement of the acyl-CoA carrier ACBD6 in myristoylation of proteins: Activation by ligand binding and protein interaction.PloS one 2022 · CEBM Level 5
- Hyperinflammation, apoptosis, and organ damage.Experimental biology and medicine (Maywood, N.J.) 2022 · CEBM Level 5
- The effects of glutamine supplementation on markers of apoptosis and autophagy in sickle cell disease peripheral blood mononuclear cells.Complementary therapies in medicine 2022 · CEBM Level 4
- Blood draw site and analytic device influence hemoglobin measurements.PloS one 2022 · CEBM Level 4
- Dual Role of ACBD6 in the Acylation Remodeling of Lipids and Proteins.Biomolecules 2022 · CEBM Level 5
- Stress and corticotropin releasing factor (CRF) promote necrotizing enterocolitis in a formula-fed neonatal rat model.PloS one 2021 · CEBM Level 5
- Time to rethink haemoglobin threshold guidelines in sickle cell disease.British journal of haematology 2021 · CEBM Level 5
- Secretory phospholipase A2 in SARS-CoV-2 infection and multisystem inflammatory syndrome in children (MIS-C).Experimental biology and medicine (Maywood, N.J.) 2021 · CEBM Level 4
- Novel, de novo, beta-globin variant with decreased oxygen affinity (HBB:c.317T>A, "Hemoglobin St. George") in a healthy child with low oxygen saturations and anemia.American journal of hematology 2021 · CEBM Level 4
- Common host variation drives malaria parasite fitness in healthy human red cells.eLife 2021 · CEBM Level 5
- The diversity of ACBD proteins - From lipid binding to protein modulators and organelle tethers.Biochimica et biophysica acta. Molecular cell research 2020 · CEBM Level 5
- Requirement of the acyl-CoA carrier ACBD6 in myristoylation of proteins: Activation by ligand binding and protein interaction.PloS one 2020 · CEBM Level 5
- ACBD6 protein controls acyl chain availability and specificity of the N -myristoylation modification of proteins.Journal of lipid research 2019 · CEBM Level 5
- Image-Based Flow Cytometry and Angle-Resolved Light Scattering to Define the Sickling Process.Cytometry. Part A : the journal of the International Society for Analytical Cytology 2019 · CEBM Level 5
- Vincristine-induced anemia in hereditary spherocytosis.Experimental biology and medicine (Maywood, N.J.) 2019 · CEBM Level 4
- Erythrocytes from hereditary xerocytosis patients heterozygous for KCNN4 V282M exhibit increased spontaneous Gardos channel-like activity inhibited by senicapoc.American journal of hematology 2017 · CEBM Level 5
- Simvastatin reduces vaso-occlusive pain in sickle cell anaemia: a pilot efficacy trial.British journal of haematology 2017 · CEBM Level 4
- Featured Article: Depletion of HDL 3 high density lipoprotein and altered functionality of HDL 2 in blood from sickle cell patients.Experimental biology and medicine (Maywood, N.J.) 2017 · CEBM Level 4
- Phosphatidylserine decarboxylase CT699, lysophospholipid acyltransferase CT775, and acyl-ACP synthase CT776 provide membrane lipid diversity to Chlamydia trachomatis.Scientific reports 2017 · CEBM Level 5
- Association of NMT2 with the acyl-CoA carrier ACBD6 protects the N-myristoyltransferase reaction from palmitoyl-CoA.Journal of lipid research 2016 · CEBM Level 5
- A look inside the mechanistic black box: Are red blood cells the critical effectors of RRx-001 cytotoxicity?Medical oncology (Northwood, London, England) 2016 · CEBM Level 5
- Featured Article: Alterations of lecithin cholesterol acyltransferase activity and apolipoprotein A-I functionality in human sickle blood.Experimental biology and medicine (Maywood, N.J.) 2016 · CEBM Level 4
- Targeting tumor hypoxia with the epigenetic anticancer agent, RRx-001: a superagonist of nitric oxide generation.Medical oncology (Northwood, London, England) 2016 · CEBM Level 5
- Microparticles as biomarkers of osteonecrosis of the hip in sickle cell disease.British journal of haematology 2015 · CEBM Level 4
- Inability to maintain GSH pool in G6PD-deficient red cells causes futile AMPK activation and irreversible metabolic disturbance.Antioxidants & redox signaling 2015 · CEBM Level 5
- Remodeling of host phosphatidylcholine by Chlamydia acyltransferase is regulated by acyl-CoA binding protein ACBD6 associated with lipid droplets.MicrobiologyOpen 2015 · CEBM Level 5
- Dysregulated arginine metabolism and cardiopulmonary dysfunction in patients with thalassaemia.British journal of haematology 2015 · CEBM Level 4
- From METS to malaria: RRx-001, a multi-faceted anticancer agent with activity in cerebral malaria.Malaria journal 2015 · CEBM Level 5
- Ligand binding to the ACBD6 protein regulates the acyl-CoA transferase reactions in membranes.Journal of lipid research 2015 · CEBM Level 5
- Sub-population analysis of deformability distribution in heterogeneous red blood cell population.Biomedical microdevices 2015 · CEBM Level 5
- Thiol/redox metabolomic profiling implicates GSH dysregulation in early experimental graft versus host disease (GVHD).PloS one 2014 · CEBM Level 5
- Elevated tricuspid regurgitant jet velocity in subgroups of thalassemia patients: insight into pathophysiology and the effect of splenectomy.Annals of hematology 2014 · CEBM Level 4
- Hemoglobin s polymerization and red cell membrane changes.Hematology/oncology clinics of North America 2014 · CEBM Level 5
- Phase 1 study of the E-selectin inhibitor GMI 1070 in patients with sickle cell anemia.PloS one 2014 · CEBM Level 4
- The capacity of red blood cells to reduce nitrite determines nitric oxide generation under hypoxic conditions.PloS one 2014 · CEBM Level 5
- Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension.Haematologica 2013 · CEBM Level 4
- A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes.Haematologica 2013 · CEBM Level 2
- RBC deformability and amino acid concentrations after hypo-osmotic challenge may reflect chronic cell hydration status in healthy young men.Physiological reports 2013 · CEBM Level 4
- A transgenic mouse model expressing exclusively human hemoglobin E: indications of a mild oxidative stress.Blood cells, molecules & diseases 2012 · CEBM Level 5
- Research in athletes with sickle cell trait: just do it.Journal of applied physiology (Bethesda, Md. : 1985) 2012 · CEBM Level 5
- Eukaryotic protein recruitment into the Chlamydia inclusion: implications for survival and growth.PloS one 2012 · CEBM Level 5
- Phosphatidylcholine formation by LPCAT1 is regulated by Ca(2+) and the redox status of the cell.BMC biochemistry 2012 · CEBM Level 5
- Compromised mitochondrial fatty acid synthesis in transgenic mice results in defective protein lipoylation and energy disequilibrium.PloS one 2012 · CEBM Level 5
- Multipotent stromal stem cells from human placenta demonstrate high therapeutic potential.Stem cells translational medicine 2012 · CEBM Level 5
- Secretory phospholipase A2: a marker of infection in febrile children presenting to a pediatric ED.The American journal of emergency medicine 2011 · CEBM Level 3
- Improved engraftment with minimal graft-versus-host disease after major histocompatibility complex-mismatched cord blood transplantation with photochemically treated donor lymphocytes.Experimental biology and medicine (Maywood, N.J.) 2011 · CEBM Level 5
- A pilot study of the short-term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction.British journal of haematology 2011 · CEBM Level 4
- A pilot study of subcutaneous decitabine in β-thalassemia intermedia.Blood 2011 · CEBM Level 4
- Tapered oral dexamethasone for the acute chest syndrome of sickle cell disease.British journal of haematology 2011 · CEBM Level 2
- Loss-of-function and gain-of-function phenotypes of stomatocytosis mutant RhAG F65S.American journal of physiology. Cell physiology 2011 · CEBM Level 5
- The effects of disruption of genes for peroxiredoxin-2, glutathione peroxidase-1, and catalase on erythrocyte oxidative metabolism.Free radical biology & medicine 2010 · CEBM Level 5
- Activity of the acyl-CoA synthetase ACSL6 isoforms: role of the fatty acid Gate-domains.BMC biochemistry 2010 · CEBM Level 5
- Tropomodulin 1-null mice have a mild spherocytic elliptocytosis with appearance of tropomodulin 3 in red blood cells and disruption of the membrane skeleton.Blood 2010 · CEBM Level 5
- Large-scale arrays of picolitre chambers for single-cell analysis of large cell populations.Lab on a chip 2010 · CEBM Level 5
- Imaging of the diffusion of single band 3 molecules on normal and mutant erythrocytes.Blood 2009 · CEBM Level 5
- Human term placenta as a source of hematopoietic cells.Experimental biology and medicine (Maywood, N.J.) 2009 · CEBM Level 5
- Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease.Blood 2008 · CEBM Level 4
- Mammalian acyl-CoA:lysophosphatidylcholine acyltransferase enzymes.Proceedings of the National Academy of Sciences of the United States of America 2008 · CEBM Level 5
- Characterization of an acyl-coenzyme A binding protein predominantly expressed in human primitive progenitor cells.Journal of lipid research 2008 · CEBM Level 5
- Mammalian long-chain acyl-CoA synthetases.Experimental biology and medicine (Maywood, N.J.) 2008 · CEBM Level 5
- Hydroxycarbamide-induced changes in E/beta thalassemia red blood cells.American journal of hematology 2008 · CEBM Level 4
- Red cell membrane lipids in hemoglobinopathies.Current molecular medicine 2008 · CEBM Level 5
- ATP8A1 activity and phosphatidylserine transbilayer movement.Journal of receptor, ligand and channel research 2008 · CEBM Level 5
- Transfusion prevents acute chest syndrome predicted by elevated secretory phospholipase A2.British journal of haematology 2007 · CEBM Level 2
- Interaction of an annexin V homodimer (Diannexin) with phosphatidylserine on cell surfaces and consequent antithrombotic activity.Thrombosis and haemostasis 2007 · CEBM Level 5
- Flow cytometric determination of PMCA-mediated Ca2+-extrusion in individual red blood cells.Cytometry. Part A : the journal of the International Society for Analytical Cytology 2007 · CEBM Level 5
- Membrane lipid alterations in hemoglobinopathies.Hematology. American Society of Hematology. Education Program 2007 · CEBM Level 5
- Hydrolysis of phosphatidylserine-exposing red blood cells by secretory phospholipase A2 generates lysophosphatidic acid and results in vascular dysfunction.The Journal of biological chemistry 2006 · CEBM Level 5
- Sulphydryl modifications alter scramblase activity in murine sickle cell disease.British journal of haematology 2006 · CEBM Level 5
- Identification of an erythroid ATP-dependent aminophospholipid transporter.British journal of haematology 2006 · CEBM Level 5
- Pulmonary hypertension in thalassemia: association with platelet activation and hypercoagulable state.American journal of hematology 2006 · CEBM Level 4
- Secretory phospholipase A2 levels in patients with sickle cell disease and acute chest syndrome.Hemoglobin 2006 · CEBM Level 4
- VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis.Nature medicine 2006 · CEBM Level 5
- Multiple erythroid isoforms of human long-chain acyl-CoA synthetases are produced by switch of the fatty acid gate domains.BMC molecular biology 2006 · CEBM Level 5
- A simple assay for frequency of chromosome breaks and loss (micronuclei) by flow cytometry of human reticulocytes.FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2005 · CEBM Level 5
- Postinjury serum secretory phospholipase A2 correlates with hypoxemia and clinical status at 72 hours.Journal of the American College of Surgeons 2005 · CEBM Level 3
- Serum C-reactive protein parallels secretory phospholipase A2 in sickle cell disease patients with vasoocclusive crisis or acute chest syndrome.Blood 2005 · CEBM Level 4
- Fetal haemoglobin augmentation in E/beta(0) thalassaemia: clinical and haematological outcome.British journal of haematology 2005 · CEBM Level 4
- Stem cell transplantation with S-59 photochemically treated T-cell add-backs to establish allochimerism in murine thalassemia.Annals of the New York Academy of Sciences 2005 · CEBM Level 5
- Single and combination drug therapy for fetal hemoglobin augmentation in hemoglobin E-beta 0-thalassemia: Considerations for treatment.Annals of the New York Academy of Sciences 2005 · CEBM Level 4
- Rescued mice with Hb E transgene-developed red cell changes similar to human beta-thalassemia/HbE disease.Annals of the New York Academy of Sciences 2005 · CEBM Level 5
- Measuring chromosome breaks in patients with thalassemia.Annals of the New York Academy of Sciences 2005 · CEBM Level 4
- Hemolysis-associated pulmonary hypertension in thalassemia.Annals of the New York Academy of Sciences 2005 · CEBM Level 5
- Reactive oxygen species and phosphatidylserine externalization in murine sickle red cells.British journal of haematology 2004 · CEBM Level 5
- Decreased arginine bioavailability and increased serum arginase activity in asthma.American journal of respiratory and critical care medicine 2004 · CEBM Level 4
- Revised nomenclature for the mammalian long-chain acyl-CoA synthetase gene family.Journal of lipid research 2004 · CEBM Level 5
- In vivo reduction of erythrocyte oxidant stress in a murine model of beta-thalassemia.Haematologica 2004 · CEBM Level 5
- Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease?American journal of respiratory and critical care medicine 2003 · CEBM Level 4
- Hydroxyurea and arginine therapy: impact on nitric oxide production in sickle cell disease.Journal of pediatric hematology/oncology 2003 · CEBM Level 4
- Selective increase of autoimmune epitope expression on aged erythrocytes in mice: implications in anti-erythrocyte autoimmune responses.Journal of autoimmunity 2002 · CEBM Level 5
- A 29-kDa protein associated with p67phox expresses both peroxiredoxin and phospholipase A2 activity and enhances superoxide anion production by a cell-free system of NADPH oxidase activity.The Journal of biological chemistry 2002 · CEBM Level 5
- Altered red cell turnover in diabetic mice.The Journal of laboratory and clinical medicine 2002 · CEBM Level 5
- Protein kinase C activation induces phosphatidylserine exposure on red blood cells.Biochemistry 2002 · CEBM Level 5